Kintara Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch KTRA and buy or sell other stocks, ETFs, and their options commission-free!

About KTRA

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The firm’s lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. 

CEO
James A. Bianco, MD
CEOJames A. Bianco, MD
Employees
19
Employees19
Headquarters
Tampa, Florida
HeadquartersTampa, Florida
Founded
Founded
Employees
19
Employees19

KTRA Key Statistics

Market cap
5.40M
Market cap5.40M
Price-Earnings ratio
-0.34
Price-Earnings ratio-0.34
Dividend yield
Dividend yield
Average volume
98.35K
Average volume98.35K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$7.93
52 Week high$7.93
52 Week low
$1.80
52 Week low$1.80

Stock Snapshot

As of today, Kintara Therapeutics(KTRA) shares are valued at $0.12. The company's market cap stands at 5.4M, with a P/E ratio of -0.34.

Kintara Therapeutics(KTRA) stock opened on 2025-12-06 at —. The price climbed to — and dipped to —.

Kintara Therapeutics(KTRA) shares are trading with a volume of 0, against a daily average of 98.35K.

In the last year, Kintara Therapeutics(KTRA) shares hit a 52-week high of $7.93 and a 52-week low of $1.80.

In the last year, Kintara Therapeutics(KTRA) shares hit a 52-week high of $7.93 and a 52-week low of $1.80.

People also own

Based on the portfolios of people who own KTRA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.